### **Overview** Aster DM Healthcare Limited is one of India’s fastest-growing and most integrated private healthcare providers, with a significant historical presence across the Gulf Cooperation Council (GCC) region and now exclusively focused on accelerating expansion in India following a strategic de-merger. The company operates under the brand promise *"We’ll Treat You Well"* and delivers healthcare services across primary, secondary, tertiary, and quaternary levels. As of November 2025, the company operates **19 hospitals**, **10 clinics**, **203 pharmacies**, and **259 labs** across five Indian states, with a dominant presence in **South India**. Headed by **Dr. Azad Moopen** and family, who bring over three decades of healthcare leadership, the group has transitioned into an India-first growth strategy following the **April 2024 divestment of its GCC operations** to Fajr Capital. --- ### **Strategic Transformation & Restructuring** - In **April 2024**, Aster completed the **operational and strategic segregation** of its India and GCC businesses, allowing the listed entity to focus solely on rapid, capital-efficient growth in India. - As part of this restructuring: - The **GCC business was sold** to a consortium led by **Fajr Capital** for an enterprise value of ~₹13,540 crore ($1.65 billion USD). - **Olympus Capital, a near 20% stakeholder, exited** the Indian business, paving the way for fresh domestic and international institutional investors. - Management was restructured: **Alisha Moopen** leads GCC operations, while **Dr. Nitish Shetty** is CEO of the Indian entity. - The restructuring allows independent capital allocation, strategic agility, and dedicated investor targeting for the Indian business. --- ### **Merger with Quality Care India Limited (QCIL) – A Landmark Integration** - The **merger with Blackstone-backed Quality Care India Limited (QCIL)**, expected to close in FY25–FY26, will create one of the **largest hospital networks in India**, combining: - Four premier brands: **Aster, CARE Hospitals, KIMSHEALTH, and Evercare** - Over **38 hospitals** and **10,150+ operational beds** across **27 cities** - **Pro forma FY25 revenue of ₹8,105 crores** and **adjusted EBITDA of ₹1,661 crores** (20.5% margin) - **Synergies & Expansion:** - The merged entity aims to scale bed capacity to **13,300+ by FY27** through greenfield and brownfield projects funded via **internal accruals**. - Minimal geographic overlap ensures **no market cannibalization** and enables entry into **four new states**: **Madhya Pradesh, Chhattisgarh, Odisha, and Tamil Nadu**. - Expected **10–15% EBITDA improvement** via supply chain consolidation, procurement rationalization, cost optimization, and shared infrastructure. - Integration will enhance clinical expertise, attract talent, and support digital transformation. --- ### **Expansion & Capacity Growth** - **Hospital Network:** - Current **5,159 operational beds** across 19 hospitals (as of Sep 2025), with an investment of **₹340 crores** in recent bed additions. - Future plans include increasing total capacity to **7,800 beds** by FY27, with major brownfield expansions at: - **Aster Medcity (Trivandrum)** – from 680 to 950 beds - **Aster CMI (Bengaluru)** – to over 850 beds - **Aster Whitefield (Bengaluru)** – to 500 beds - A new **430-bed Aster multispecialty hospital** is under development at **Sarjapur, Bengaluru**, with Phase 1 (300 beds) launching in **H2 FY27**. - **Asset-Light O&M Model:** - Expanding via **Operations & Management** (O&M) agreements to drive growth in Tier 2/3 cities with low capex. - Examples include **Aster Narayanadri (Tirupati, 150 beds)** and **Aster Mother Hospital (Areekode, 140 beds)**, both achieving **breakeven within 3–6 months**. - **Targeted Clusters:** - **Mature hospitals** (e.g., Trivandrum, Dhaka): 14% YoY revenue growth, 22% EBITDA growth - **Emerging units** (e.g., Nagercoil): 78% YoY revenue growth - **Hyderabad cluster undergoing turnaround** with leadership changes, new systems, and infrastructure upgrades. - The company remains committed to achieving **70% of revenue from Tier 2 and Tier 3 cities**, leveraging early-mover advantage and brand loyalty. --- ### **Financials & Operational Strength** - **Capital Position:** - **Net cash of ₹739 crores** despite capital investments. - **Gross debt: ₹642 crores** - Expansion funded primarily through **internal accruals**, maintaining balance sheet resilience. - **Profitability & Efficiency:** - **Hospital EBITDA margin: 22.3% (9M FY25)**, up from 19.5% YoY, with mature units achieving **25% EBITDA margins** and **36% ROCE**. - **Average Revenue Per Occupied Bed (ARPOB): ₹38,000–₹70,000**, varying with geography and specialty. - No single specialty exceeds **15% of revenue**, creating a diversified, de-risked portfolio. --- ### **Digital Transformation: Aster Digital Health** - **Aster Digital Health** is a core vertical, integrating: - **Aster Health App**: Launched FY25, with **100,000+ downloads** and **20,000 monthly active users**. - Supports appointment booking, video consultations, digital records, and a **regional version in Malayalam** (first such super app in Kerala). - **Aster Care**: A patient journey platform with **79% engagement rate** at flagship hospitals. - **AI & Data Innovation:** - Development of a **centralized data lake** in collaboration with IISc and Intel for AI-driven clinical insights. - AI tools in development: **Nerve tracking during surgery**, **Chest X-ray interpretation**, **Federated Learning** platform for secure data sharing. - Partnerships with **LTTS, Logy.AI, and CARPL** to co-develop next-gen diagnostics. - **Telehealth & Remote Care:** - **Telehealth Command Centre** in Bengaluru supports teleradiology, tele-ICU, and remote monitoring. - Home-based chronic care programs for **diabetes and hypertension**. --- ### **Diagnostics & Pharmacy Verticals** - **Aster Labs:** - Operates **259 labs & Patient Experience Centers (PECs)** as of Oct 2025, with advanced capabilities in molecular biology and immunohistochemistry. - Achieved **>12% YoY revenue growth** in FY25; now **EBITDA-positive (~8%)**. - **28% revenue from third-party/external patients** (up from 23%), with a goal to reach **50%**, which could elevate lab EBITDA margins **above 20%**. - Expansion is **capital-light**, adding only new collection centers. - **Aster Pharmacies:** - Operates **203 retail stores** via **Alfaone Retail Pharmacies (ARPPL)** under a brand license. - Focus on **profitability and private labels**, with plans to achieve **breakeven by FY26 (mid-single-digit margins)**. - No major retail expansion planned; focus on **same-store sales increase** and **E-commerce launch**. --- ### **Specialty & Clinical Excellence** - **Focus on High-Acuity Care:** - Over **55% of procedures are high-complexity (CONGO)**. - Generates **~58% of revenue** from key specialties: **Cardiac Sciences, Neurology, Oncology, Gastro-Liver, Orthopaedics, and Nephrology**. - **Pioneering Initiatives:** - **Precision Oncology Clinics**, **Aster Cancer Grid**, and **Onco Collect** for personalized cancer care. - **India’s first Intra-Operative Electron Radiation Therapy (IOERT)** at Aster Whitefield’s **International Institute of Oncology**. - Over **300 transplants and 1,140+ robotic surgeries annually**. - **Quality & Accreditation:** - 9 hospitals hold **NABH Digital Accreditation**, with MIMS and Medcity among the first in Kerala to receive platinum-level certification. - QCIL’s facilities are **100% NABH-accredited**, with one holding **JCI accreditation**. --- ### **Medical Value Travel (MVT) & Wellness** - **MVT Growth:** - A core growth driver, attracting patients from **GCC, Africa, Maldives, Bangladesh, Afghanistan, and SAARC**. - **FY25 MVT revenue: ₹150 crores**, with **₹33.2 crores in Q1 FY26** and a **monthly run rate of ₹15–20 crores**. - Projected FY26 revenue: **₹180–200 crores**. - Dedicated clusters in **Kerala and Bengaluru**. - Strategy includes **channel partnerships, service differentiation, and market diversification**. - **Wellness & Palliative Care:** - **Palliative care teams** (nurses, psychologists, nutritionists) deliver holistic, personalized care. - Launched **Wellth by Medcare**, a wellness hub in Dubai offering anti-ageing, sleep therapy, and regenerative medicine. - **Aster@Home**: Provides nurse visits, lab collections, and pharmacy delivery; launched after acquiring Wahat Al Aman Home Health in Abu Dhabi.